Guardant Health, Inc. current report, Q3 FY2025

Guardant Health, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Guardant Health, Inc. on September 12, 2025. The filing reports a corporate governance event involving the expansion of the Board of Directors and the appointment of a new director.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.

Material Changes

  • Board Expansion: The Board of Directors increased the number of directors from 10 to 11.
  • New Appointment: Alex M. Azar II, former U.S. Secretary of Health and Human Services, was appointed as a Class III director effective September 12, 2025.
  • Committee Assignment: Mr. Azar was appointed to the Nominating and Corporate Governance Committee.

Compensation and Governance Details

Mr. Azar will receive standard non-employee director compensation under the Company's Amended Non-Employee Director Compensation Program. His initial awards include:

  • A stock option award valued at $362,500.
  • A restricted stock unit (RSU) award valued at $362,500.

Vesting Schedule: One-fourth (1/4) of the shares vest on the first anniversary of the appointment. The remaining three-fourths (3/4) vest monthly over the subsequent three-year period, contingent on continued service. The Company also entered into a standard indemnification agreement with Mr. Azar.

Investor Verification Checklist

  • Verify the total number of directors on the Board is now 11.
  • Confirm the vesting schedule for the $725,000 total initial equity award granted to Mr. Azar.
  • Review the attached Press Release (Exhibit 99.1) for additional context on the appointment.
  • Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.